Immunoinhibitory checkpoint pathways (cytotoxic T lymphocyte-associated protein-4 [CTLA-4]/B7, programmed cell death-1 [PD-1]/programmed cell death ligand-1 [PD-L1]) are emerging as interesting immunotherapeutic targets for the treatment of cancer. This evidence concerns the gene PDCD1 and cancer.